Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) Equity Average (2016 - 2025)

Historic Equity Average for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to $3.2 million.

  • Alaunos Therapeutics' Equity Average fell 47.73% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 47.73%. This contributed to the annual value of $4.2 million for FY2024, which is 8126.03% down from last year.
  • Alaunos Therapeutics' Equity Average amounted to $3.2 million in Q3 2025, which was down 47.73% from $2.4 million recorded in Q2 2025.
  • Alaunos Therapeutics' 5-year Equity Average high stood at $114.8 million for Q1 2021, and its period low was $1.6 million during Q1 2025.
  • Over the past 5 years, Alaunos Therapeutics' median Equity Average value was $25.6 million (recorded in 2023), while the average stood at $33.3 million.
  • As far as peak fluctuations go, Alaunos Therapeutics' Equity Average tumbled by 8368.59% in 2024, and later tumbled by 47.73% in 2025.
  • Over the past 5 years, Alaunos Therapeutics' Equity Average (Quarter) stood at $63.4 million in 2021, then crashed by 44.25% to $35.3 million in 2022, then crashed by 71.41% to $10.1 million in 2023, then crashed by 76.13% to $2.4 million in 2024, then soared by 34.0% to $3.2 million in 2025.
  • Its Equity Average stands at $3.2 million for Q3 2025, versus $2.4 million for Q2 2025 and $1.6 million for Q1 2025.